Some miRNAs have been reported to target HAS2 in physiopathologic process, which including miR-26b in ovarian granulosa cell apoptosis [36], miR-574 in oocyte maturation [37], and miR-101-3p in synovial sibroblasts [38] etc. However, there was no report about miRNA-regulating the expression of HAS2 during cancer development. The gene discussed is HAS2; the disease is cancer.